We are live on ! Find out more
CLDI.WS

Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS

Delisted

CLDI.WS was delisted on the 17th of October, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $1.01K → $0 (-$1.01K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
EAM
Exos Asset Management
New York
-$1.01K
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Exos Asset Management
New York
– -$1.01K -105,000 Closed

CLDI.WS Hedge Fund Activity: Q1 2025 in Review

0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q1 2025, worth a combined $0 — down 100% from $1.01K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CLDI.WS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Exos Asset Management, exiting entirely with an estimated $1.01K sold.

  • 0 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q1 2025, down from 1 in Q4 2024.
  • Funds reported $0 of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q1 2025 and 1 closed out, a net change of -1 holder.
  • The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q1 2025 was Exos Asset Management, an estimated $1.01K sold.

Based on aggregated 13F filings for Q1 2025.